P2RY12 and Stroke: A recent meta‐analysis of randomized patients receiving either P2Y12 inhibitor monotherapy or aspirin monotherapy for secondary prevention concluded that the risk of all‐cause death, vascular death, and stroke did not differ, but that the risk of MI was marginally lower in those receiving a P2Y12 inhibitor, with a number needed to treat of 244 patients to prevent one event.56